(MedPage Today) — Ocrelizumab (Ocrevus) delayed overall disability progression and worsening of upper limb function in people with primary progressive multiple sclerosis (PPMS) over 144 weeks, the ORATORIO-HAND (O’HAND) trial showed.
In a large…
Source link : https://www.medpagetoday.com/meetingcoverage/ectrims/117700
Author :
Publish date : 2025-09-29 19:06:00
Copyright for syndicated content belongs to the linked Source.
